Suppr超能文献

造血细胞移植中的间充质基质细胞

Mesenchymal stromal cells in hematopoietic cell transplantation.

作者信息

Burnham Andre J, Daley-Bauer Lisa P, Horwitz Edwin M

出版信息

Blood Adv. 2020 Nov 24;4(22):5877-5887. doi: 10.1182/bloodadvances.2020002646.

Abstract

Mesenchymal stromal cells (MSCs) are widely recognized to possess potent immunomodulatory activity, as well as to stimulate repair and regeneration of diseased or damaged tissue. These fundamental properties suggest important applications in hematopoietic cell transplantation. Although the mechanisms of therapeutic activity in vivo are yet to be fully elucidated, MSCs seem to suppress lymphocytes by paracrine mechanisms, including secreted mediators and metabolic modulators. Most recently, host macrophage engulfment of apoptotic MSCs has emerged as an important contributor to the immune suppressive microenvironment. Although bone marrow-derived MSCs are the most commonly studied, the tissue source of MSCs may be a critical determinant of immunomodulatory function. The key application of MSC therapy in hematopoietic cell transplantation is to prevent or treat graft-versus-host disease (GVHD). The pathogenesis of GVHD reveals multiple potential targets. Moreover, the recently proposed concept of tissue tolerance suggests a new possible mechanism of MSC therapy for GVHD. Beyond GVHD, MSCs may facilitate hematopoietic stem cell engraftment, which could gain greater importance with increasing use of haploidentical transplantation. Despite many challenges and much doubt, commercial MSC products for pediatric steroid-refractory GVHD have been licensed in Japan, conditionally licensed in Canada and New Zealand, and have been recommended for approval by an FDA Advisory Committee in the United States. Here, we review key historical data in the context of the most salient recent findings to present the current state of MSCs as adjunct cell therapy in hematopoietic cell transplantation.

摘要

间充质基质细胞(MSCs)具有强大的免疫调节活性以及刺激患病或受损组织修复和再生的能力,这已得到广泛认可。这些基本特性表明其在造血细胞移植中具有重要应用。尽管MSCs在体内的治疗活性机制尚未完全阐明,但它们似乎通过旁分泌机制抑制淋巴细胞,包括分泌介质和代谢调节剂。最近,宿主巨噬细胞吞噬凋亡的MSCs已成为免疫抑制微环境的重要促成因素。尽管骨髓来源的MSCs是研究最广泛的,但MSCs的组织来源可能是免疫调节功能的关键决定因素。MSCs治疗在造血细胞移植中的关键应用是预防或治疗移植物抗宿主病(GVHD)。GVHD的发病机制揭示了多个潜在靶点。此外,最近提出的组织耐受概念为MSCs治疗GVHD提供了一种新的可能机制。除了GVHD,MSCs可能促进造血干细胞植入,随着单倍体相合移植的使用增加,这一点可能变得更加重要。尽管存在许多挑战和质疑,但用于治疗儿童类固醇难治性GVHD的商业MSCs产品已在日本获得许可,在加拿大和新西兰有条件获得许可,并已被美国食品药品监督管理局咨询委员会推荐批准。在此,我们结合最近最突出的研究结果回顾关键的历史数据,以呈现MSCs作为造血细胞移植辅助细胞治疗的现状。

相似文献

1
Mesenchymal stromal cells in hematopoietic cell transplantation.
Blood Adv. 2020 Nov 24;4(22):5877-5887. doi: 10.1182/bloodadvances.2020002646.
5
[Mesenchymal stem cell therapy in hematopoietic stem cell transplantation].
Rinsho Ketsueki. 2018;59(2):195-204. doi: 10.11406/rinketsu.59.195.
6
Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice.
Ann Hematol. 2013 Oct;92(10):1295-308. doi: 10.1007/s00277-013-1796-z. Epub 2013 May 31.
9
Mesenchymal Stromal Cells in Hematopoietic Stem Cell Transplantation.
Methods Mol Biol. 2016;1416:3-20. doi: 10.1007/978-1-4939-3584-0_1.
10
Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?
Front Immunol. 2020 Dec 11;11:609063. doi: 10.3389/fimmu.2020.609063. eCollection 2020.

引用本文的文献

2
BNIP3 induced by hypoxia supports the survival of mesenchymal stromal cells (MSCs) after intravenous cell transplantation.
Regen Ther. 2025 Jun 19;30:224-233. doi: 10.1016/j.reth.2025.06.005. eCollection 2025 Dec.
3
Mesenchymal Stromal Cells and Graft-versus-Host Disease: Preclinical and Clinical Studies.
Stem Cell Rev Rep. 2025 Jun 14. doi: 10.1007/s12015-025-10914-8.
4
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer.
Exp Hematol Oncol. 2025 May 2;14(1):66. doi: 10.1186/s40164-025-00654-3.
5
A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy.
Extracell Vesicles Circ Nucl Acids. 2025 Mar 25;6(1):183-190. doi: 10.20517/evcna.2025.02. eCollection 2025.
7
Study on the changes of human bone marrow‑related mesenchymal stem cells.
Int J Mol Med. 2025 Feb;55(2). doi: 10.3892/ijmm.2024.5464. Epub 2024 Nov 29.
10
Transcriptomic analysis of BM-MSCs identified EGR1 as a transcription factor to fully exploit their therapeutic potential.
Biochim Biophys Acta Mol Cell Res. 2024 Dec;1871(8):119818. doi: 10.1016/j.bbamcr.2024.119818. Epub 2024 Aug 19.

本文引用的文献

1
Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.
Biol Blood Marrow Transplant. 2020 May;26(5):855-864. doi: 10.1016/j.bbmt.2020.01.026. Epub 2020 Feb 7.
3
PDGFB-expressing mesenchymal stem cells improve human hematopoietic stem cell engraftment in immunodeficient mice.
Bone Marrow Transplant. 2020 Jun;55(6):1029-1040. doi: 10.1038/s41409-019-0766-z. Epub 2019 Dec 5.
4
Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells.
Front Immunol. 2019 Nov 19;10:2685. doi: 10.3389/fimmu.2019.02685. eCollection 2019.
5
8
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.
Cell Stem Cell. 2018 Jun 1;22(6):824-833. doi: 10.1016/j.stem.2018.05.004.
10
Fetal Mesenchymal Stromal Cells: an Opportunity for Prenatal Cellular Therapy.
Curr Stem Cell Rep. 2018;4(1):61-68. doi: 10.1007/s40778-018-0118-8. Epub 2018 Feb 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验